Vertex acquired rights to Concert Pharmaceuticals’s cystic fibrosis drug CTP-656. The drug is a deuterated version of Vertex’s own compound ivacaftor, which it sells under the name Kalydeco.
CTP-656 Currently in Phase II clinical trials. The deal avoided a potential litigation between the two companies.
